140829 Edanz Mie
-
Upload
edanz-group -
Category
Education
-
view
111 -
download
2
Transcript of 140829 Edanz Mie
Jeffrey Robens, PhD Senior Research Consultant
Education Group Leader
Publishing Clinical Research: Increasing your chances of acceptance
Mie University
29 August 2014
Be an effective communicator
S
Your goal is not only to be published, but also to be widely read/cited
Good experimental design
Logically present your work in your manuscript
Choose the best journal to reach your target audience
Convey the significance of your work to journal editors
Section 1
Good experimental design
Experimental design
What do international journal editors want?
Interesting to journal’s readership
Increase impact
High quality research
Original and novel research Well-designed
study Clinical applications
Experimental design
What do international journal editors want?
Clinical relevance
Technical quality
Novelty
CT scans of 1000 patients with gliomas
Experimental design
What do international journal editors want?
Clinical relevance
Technical quality
Novelty CT scans of Japanese glioma patients raised in Japan or the US
Experimental design
What do international journal editors want?
Clinical relevance
Technical quality
Novelty
CT scans of younger and older Japanese glioma patients
Experimental design
Clinical research that has impact
1. Read primary literature
2. Read systematic reviews and meta-analyses
3. Identify an important question
• Is the question focused? • Do you have the expertise/resources? • What is new? • How is it clinically useful?
Experimental design Clinical trial registration
Not required for observational studies
Retrospective registration is sometimes possible
Should be registered before journal submission
Treatments/interventions are not assigned by the investigator
Where to register? ClinicalTrials.gov
UMIN Clinical Trials Registry (umin.ac.jp)
Section 2
Manuscript structure
Manuscript structure Reporting guidelines
CONSORT Randomized clinical trials
PRISMA Systematic reviews &
Meta-analyses
CARE Case reports
STROBE Observational studies
http://www.equator-network.org/
Manuscript structure Writing clinical abstracts
Background Why does this trial/case
need to be reported?
Results Treatment outcomes
Adverse events
Conclusion Clinical relevance Learning points
Patients and methods
Patient information Interventions given
Concise summary of your study
List source of funding and trial registration number after abstract
Manuscript structure Introduction
General introduction
Specific aims Aims
Current state of the field
Problem in the field
Manuscript structure
Molecular markers help clinicians manage metastatic breast cancer systemically by indicating when endocrine therapy, chemotherapy, or HER2–targeted therapy
(such as trastuzumab or lapatinib) is appropriate.
However, previous studies have suggested the possibility of discordant HER2 status between primary and metastatic tumors.
Furthermore, to the best of our knowledge, there have been no previous studies evaluating
whether clinical factors affect these discordance rates.
Aims: Determine the discordance rates of HER2 in primary and metastatic tumors and determine if they are influenced by trastuzumab and/or chemotherapy
Niikura et al. J Clin Oncol 2011; 30: 593–599.
Introduction – Structure of ideas
Manuscript structure
Aims: Determine the discordance rates of HER2 in primary and metastatic tumors and determine if they are influenced by trastuzumab and/or chemotherapy
Importance of biomarkers for determining appropriate therapy
Potential difference between primary and metastatic tumors
Not known what causes this difference
Study objectives
Niikura et al. J Clin Oncol 2011; 30: 593–599.
Introduction – Structure of ideas
Manuscript structure Methods
How the study was done
Treatments (controls) Patient management
Follow-up
Quantification methods Statistical tests
Participants used
Demographics Enrollment procedure
Inclusion/exclusion criteria
Data analysis
Study design
Manuscript structure Results
1. Study design 2. Treatment efficacy 3. Safety
Each subsection corresponds to
one figure
What you found, not what it means
Logical presentation
Subsections
Factual description
Manuscript structure Discussion
Summary of findings
Relevance of findings
Clinical implications
Similarities/differences Unexpected results Negative results Limitations
Manuscript structure Linking your ideas
General background
Objectives
Methodology
Results and figures
Summary of findings
Clinical implications
Clinical relevance
Problem in the field
Logically links your ideas throughout your manuscript
Current state of the field Introduction
Methods
Results
Discussion
Manuscript structure
Case reports – essential elements
Presents an important unreported case
Tell a story, a timeline of events
Short, 500–1500 words
Needs to have educational value in addition to novelty
Kukreja et al. BMJ Case Reports 2011.
Manuscript structure
Background Concise description of
the disease or treatment
Case presentation
Patient information Diagnostic tests and results
Interventions Follow-up
Discussion Interpret the findings
Relationship with other cases Implications for the field
Case reports – structure of ideas
• Clinical implications • Educational value • Future directions
Section 3
Communicating with journals
Coverage and Staffing Plan
Communicating with journals Factors to consider
Aims & scope Readership
Open access Impact factor
Which factor is most important to you?
Indexing
Coverage and Staffing Plan
Communicating with journals Evaluating significance
How new are your findings? Novelty
How broadly relevant are your findings? Relevance
What are the important clinical implications? Appeal
Coverage and Staffing Plan
Communicating with journals
Journal Selector www.edanzediting.co.jp/journal_selector
Insert your proposed abstract
Coverage and Staffing Plan
Communicating with journals
Recommended journals
Filter by: • Impact factor • Publishing frequency • Open access
Journal Selector www.edanzediting.co.jp/journal_selector
Coverage and Staffing Plan
Communicating with journals
Journal’s aims & scope, IF, and publication frequency
Are they currently publishing similar articles?
Similar published articles
Have you cited any of these articles?
Journal Selector www.edanzediting.co.jp/journal_selector
www.biomedcentral.com/authors/authorfaq/findout
Coverage and Staffing Plan
Communicating with journals
Dear Dr Lippman,
Please find enclosed our manuscript entitled “Evaluation of the Glasgow prognostic score in patients undergoing curative
resection for breast cancer liver metastases,” which we would like to submit for publication as an Original Article in the Breast
Cancer Research and Treatment.
The Glasgow prognostic score (GPS) is of value for a variety of tumours. Several studies have investigated the prognostic value of the GPS in patients with metastatic breast cancer, but few studies have performed such an investigation for patients undergoing liver resection for liver metastases. Furthermore, there are currently no studies that have examined the prognostic value of the modified GPS (mGPS) in these patients. The present study evaluated the mGPS in terms of its prognostic value for postoperative death in patients undergoing liver resection for breast cancer liver metastases.
A total of 318 patients with breast cancer liver metastases who underwent hepatectomy over a 15-year period were included in this study. The mGPS was calculated based on the levels of C-reactive protein and albumin, and the disease-free survival and cancer-specific survival rates were evaluated in relation to the mGPS. Prognostic significance was retrospectively analyzed by univariate and multivariate analyses. Overall, the results showed a significant association between cancer-specific survival and the mGPS and carcinoembryonic antigen level, and a higher mGPS was associated with increased aggressiveness of liver recurrence and poorer survival in these patients. This study is the first to demonstrate that the preoperative mGPS, a simple clinical tool, is a useful prognostic factor for postoperative survival in patients undergoing curative resection for breast cancer liver metastases. This information is immediately clinically applicable for oncologists treating such patients. As a premier journal covering the broad field of cancer, we believe that the Breast Cancer Research and Treatment is the perfect platform from which to share our results with the international medical community.
Give the background to the research
What was done and what was found
Interest to journal’s readers
A good cover letter
We would also like to suggest the following reviewers for our manuscript…
Editor’s name Manuscript title
Publication type
Recommend reviewers
Publication ethics disclaimers
Coverage and Staffing Plan
Communicating with journals
Recommending reviewers
Where to find them?
From your reading/references, networking at conferences
How senior? Aim for mid-level researchers
Who to avoid? Collaborators (past 5 years),
researchers from same institution
International list: 1 or 2 from Asia, 1 or 2 from Europe, and 1 or 2 from North America
Have they published in your target journal?
Acceptance checklist
Well-designed study with proper controls
Publically registered trial
Logically organized manuscript
Appropriate journal selection
Cover letter (+ CONSORT/STROBE)
Thank you!
Any questions?
Follow us on Twitter
@JournalAdvisor
Like us on Facebook
facebook.com/EdanzEditing
Download and further reading www.edanzediting.co.jp/mie_2014
Jeffrey Robens: [email protected]